Literature DB >> 25082859

MDSCs: the final frontier of the microenvironment in CLL?

Katja Zirlik1.   

Abstract

In this issue of Blood, Jitschin et al identify increased numbers of myeloid-derived suppressor cells (MDSCs) in untreated patients with chronic lymphocytic leukemia (CLL) suppressing T cells and inducing regulatory T cells (T(regs)), resulting in impaired immune responses.

Entities:  

Mesh：

Year:  2014        PMID： 25082859      PMCID： PMC4118477          DOI： 10.1182/blood-2014-06-578880

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

1.  Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL.

Authors:  Petros Christopoulos; Dietmar Pfeifer; Kilian Bartholomé; Marie Follo; Jens Timmer; Paul Fisch; Hendrik Veelken
Journal:  Blood       Date:  2011-01-26       Impact factor: 22.113

2.  CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs.

Authors:  Regina Jitschin; Martina Braun; Maike Büttner; Katja Dettmer-Wilde; Juliane Bricks; Jana Berger; Michael J Eckart; Stefan W Krause; Peter J Oefner; Katarina Le Blanc; Andreas Mackensen; Dimitrios Mougiakakos
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

Review 3.  The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies.

Authors:  Jan A Burger; John G Gribben
Journal:  Semin Cancer Biol       Date:  2013-09-07       Impact factor: 15.707

4.  Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL).

Authors:  Michael P Gustafson; Roshini S Abraham; Yi Lin; Wenting Wu; Dennis A Gastineau; Clive S Zent; Allan B Dietz
Journal:  Br J Haematol       Date:  2011-11-03       Impact factor: 6.998

5.  IDO is a nodal pathogenic driver of lung cancer and metastasis development.

Authors:  Courtney Smith; Mee Young Chang; Katherine H Parker; Daniel W Beury; James B DuHadaway; Hollie E Flick; Janette Boulden; Erika Sutanto-Ward; Alejandro Peralta Soler; Lisa D Laury-Kleintop; Laura Mandik-Nayak; Richard Metz; Suzanne Ostrand-Rosenberg; George C Prendergast; Alexander J Muller
Journal:  Cancer Discov       Date:  2012-07-19       Impact factor: 39.397

6.  Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease.

Authors:  Giovanni D'Arena; Luca Laurenti; Maria Marta Minervini; Silvia Deaglio; Lisa Bonello; Laura De Martino; Laura De Padua; Lucia Savino; Michela Tarnani; Vincenzo De Feo; Nicola Cascavilla
Journal:  Leuk Res       Date:  2010-09-28       Impact factor: 3.156

Review 7.  The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.

Authors:  Dennis Lindau; Paul Gielen; Michiel Kroesen; Pieter Wesseling; Gosse J Adema
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

8.  Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.

Authors:  Raanan Berger; Rinat Rotem-Yehudar; Gideon Slama; Shimon Landes; Abraham Kneller; Merav Leiba; Maya Koren-Michowitz; Avichai Shimoni; Arnon Nagler
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

9.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia.

Authors:  Maciej Grzywnowicz; Joanna Zaleska; Daniel Mertens; Waldemar Tomczak; Paulina Wlasiuk; Kamila Kosior; Agnieszka Piechnik; Agnieszka Bojarska-Junak; Anna Dmoszynska; Krzysztof Giannopoulos
Journal:  PLoS One       Date:  2012-04-19       Impact factor: 3.240
  10 in total
  6 in total

Review 1.  CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma.

Authors:  Gunilla Enblad; Hannah Karlsson; Angelica S I Loskog
Journal:  Hum Gene Ther       Date:  2015-08       Impact factor: 5.695

Review 2.  Myeloid derived suppressor cells in chronic myeloid leukemia.

Authors:  Cesarina Giallongo; Nunziatina Parrinello; Maria Violetta Brundo; Salvatore Antonino Raccuia; Michelino Di Rosa; Piera La Cava; Daniele Tibullo
Journal:  Front Oncol       Date:  2015-05-15       Impact factor: 6.244

3.  Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.

Authors:  Agata A Filip; Anna Grenda; Sylwia Popek; Dorota Koczkodaj; Małgorzata Michalak-Wojnowska; Michał Budzyński; Ewa Wąsik-Szczepanek; Szymon Zmorzyński; Agnieszka Karczmarczyk; Krzysztof Giannopoulos
Journal:  Ann Hematol       Date:  2016-10-12       Impact factor: 3.673

Review 4.  Can Dendritic Cell Vaccination Prevent Leukemia Relapse?

Authors:  Liam J O'Brien; Camille Guillerey; Kristen J Radford
Journal:  Cancers (Basel)       Date:  2019-06-22       Impact factor: 6.575

Review 5.  Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.

Authors:  Carlos Cuesta-Mateos; Jennifer R Brown; Fernando Terrón; Cecilia Muñoz-Calleja
Journal:  Front Immunol       Date:  2021-03-24       Impact factor: 7.561

6.  Quantitative Temporal in Vivo Proteomics Deciphers the Transition of Virus-Driven Myeloid Cells into M2 Macrophages.

Authors:  Derek R Clements; John Patrick Murphy; Andra Sterea; Barry E Kennedy; Youra Kim; Erin Helson; Shekoufeh Almasi; Namit Holay; Prathyusha Konda; Joao A Paulo; Tanveer Sharif; Patrick W Lee; Michael P Weekes; Steven P Gygi; Shashi Gujar
Journal:  J Proteome Res       Date:  2017-08-23       Impact factor: 4.466
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.